Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03190018
Other study ID # Tmed-005 (Gothenburg)
Secondary ID
Status Completed
Phase N/A
First received May 27, 2017
Last updated April 16, 2018
Start date June 1, 2017
Est. completion date March 31, 2018

Study information

Verified date May 2017
Source Triomed AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a proof-of-concept of peritoneal dialysis with the Carry Life System for Peritoneal Dialysis (CLS PD). The extra-corporeally absorption of uremic toxins and certain ions from the recirculated peritoneal fluid by the Purcart are evaluated together with the achievement of a stable intraperitoneal osmolarity.


Description:

Each patient will be studied during a daytime treatment session of 8 hours. After the inclusion criteria have been met the patient will undergo a Personal Dialysis Capacity test (PDC) to establish the characteristics of the peritoneal membrane, which is required for the individual glucose-salt setting in the device. An ECG and coagulation status will also be performed at this visit.

The clinical study requires the insertion of a temporary catheter (Pigtail) in addition to the patients existing standard PD catheter, and it will be inserted on the morning of the study session. Once the temporary catheter is in situ the peritoneal cavity is filled with a standard glucose based PD solution. Heparin will be added to the PD solution to prevent clogging of the CLS PD. The device is then connected to the catheters and the temporary catheter is used for inflow and positioned in the upper right abdominal quadrant whereas the standard PD catheter in the lower quadrant is used for outflow.

During the study session, a glucose-salt solution will be delivered at a set rate according to individual prescriptions based on the PDC-test and a dosage table based on an algorithm. The osmolarity of the intraperitoneal fluid should be approximately 325 mOsmol/L to obtain an average ultrafiltration of roughly 100 ml/h. It is possible to adjust the delivery rate of the glucose-salt solution during the study session to maintain the desired osmolarity.

The Purcart used for removal of uremic toxins requires replacement after 4 hours of treatment. The use of two Purcarts during the eight-hour study session will provide adequate information with regard to the efficacy of toxin removal.

After the study session, the temporary catheter will be removed and the patient will be hospitalized overnight for observation. The patient will resume their previous PD therapy 36 hours after the study session. The patient's experience of the treatment will be recorded and a follow-up will be performed within 1 week after the study session.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date March 31, 2018
Est. primary completion date March 13, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female patients, >18 years of age.

- Prevalent PD patients with ESRD on stable PD without clinical signs of dehydration

- Obtained written consent to participate in the study.

- Negative pregnancy test in females of childbearing age.

Exclusion Criteria:

- Active malignant disease.

- On-going infection.

- HIV and/or hepatitis positive.

- Pregnant, breastfeeding or women of childbearing potential without adequate contraceptive precautions.

- Abdominal hernias.

- Previous major abdominal surgery.

- Any coagulation disorders.

- Anticoagulant therapy within 7 days prior to the study session.

- Allergy to Ecvacillin or Heparin

- Decompensated heart failure

- Conditions except the previous that the Investigator assesses as unsuitable for participation.

- Participation in other clinical trials, which can interfere with this study, within one month before inclusion.

Study Design


Intervention

Device:
lCarry Life System Peritoneal Dialysis (CLS PD)
The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.

Locations

Country Name City State
Sweden Sahlgrenska University Hospital Gothenburg Västra Götalands Regionen

Sponsors (1)

Lead Sponsor Collaborator
Triomed AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary The change in uremic toxins during the study session Measure the uremic toxins before and after the study session to calculate their removal During the eight-hour study session
Primary Maintain stable intraperitoneal osmolarity Measurement of Glucose and Sodium in the intraperitoneal fluid during the study session During the eight-hour study session
Primary Measure ultrafiltered volume The calculated difference between total output minus total fluid intake During the eight-hour study session
Secondary Open questions associated with the CLS PD The patient will answer open questions objectively describing the portability of the device, sensation associated with the transfer of intraperitoneal fluid in and out of the abdomen and other treatment related viewpoints. During eight-hour study session
Secondary Any Adverse Event (AE) or Serious Adverse Event (SAE) and any Adverse Device Effect (ADE) or Serious Adverse Device Effect (SADE). Electrolytes and glucose will be measured both in the blood and the intraperitoneal fluid during the study sessions. The incidence of treatment emergent adverse events or adverse device events occurring during the study Followed during a three week period from visit 2 to visit 4 (1 day follow-up)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04925674 - Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis. Phase 1
Terminated NCT03438877 - Intensive Versus Regular Dosage For PD In AKI. N/A
Completed NCT05149508 - Intraperitoneal Pressure Measurements in Children
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Withdrawn NCT03019159 - Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis N/A
Recruiting NCT01195519 - The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis N/A
Recruiting NCT06351007 - Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK) N/A
Not yet recruiting NCT04628117 - Effect of Oral Nutritional Supplementation on Oxidative Stress in Protein-energy Wasting Patients With Peritoneal Dialysis N/A
Recruiting NCT05449067 - CAPD Versus APD in Nondiabetic Peritoneal Dialysis Patients N/A
Not yet recruiting NCT03953950 - Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients Phase 4
Completed NCT02128347 - Effectiveness of an Online Portal for Delivery of Care to Home Dialysis Patients N/A
Completed NCT01209273 - Comparison of Quality of Life on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis N/A
Completed NCT00734552 - Study to Evaluate the Protective Effect of α-Keto Acid With Low-protein Diet on Renal Function in PD Patients N/A
Not yet recruiting NCT06096558 - The Effects of Melatonin on Cardiovascular and Bone Metabolism Markers in Peritoneal Dialysis Patients N/A
Completed NCT04413266 - Effects of Curcumin Supplementation in Patients With Chronic Kidney Disease on Peritoneal Dialysis N/A
Not yet recruiting NCT06060951 - Relating Abdominal Complications With Peritoneal Pressure Estimation and Reporting
Completed NCT03980795 - Exercise in Peritoneal Dialysis Patients (PDEX) N/A
Not yet recruiting NCT02270229 - Evaluation of the Peritoneal Dialysis Program in a Hospital in Chinandega, Nicaragua. N/A
Completed NCT02347592 - Peritoneal Dialysis Catheter Function N/A
Withdrawn NCT00397358 - Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients Phase 4